Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Short Interest Update

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) saw a large drop in short interest in the month of September. As of September 30th, there was short interest totalling 96,900 shares, a drop of 55.1% from the September 15th total of 215,900 shares. Based on an average daily volume of 674,000 shares, the days-to-cover ratio is currently 0.1 days.

Analyst Upgrades and Downgrades

Separately, Bank of America raised Bayer Aktiengesellschaft from an "underperform" rating to a "neutral" rating in a report on Friday, September 6th. One analyst has rated the stock with a sell rating and eight have issued a hold rating to the company. Based on data from MarketBeat, Bayer Aktiengesellschaft currently has a consensus rating of "Hold".

Bayer Aktiengesellschaft Stock Down 1.4 %

Shares of BAYRY stock traded down $0.10 during trading hours on Friday, reaching $7.25. 497,482 shares of the stock traded hands, compared to its average volume of 1,363,508. The business has a fifty day moving average price of $7.75 and a 200 day moving average price of $7.52. Bayer Aktiengesellschaft has a 1-year low of $6.82 and a 1-year high of $11.71. The company has a quick ratio of 0.86, a current ratio of 1.27 and a debt-to-equity ratio of 1.04.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last released its earnings results on Tuesday, August 6th. The company reported $0.25 earnings per share for the quarter, meeting the consensus estimate of $0.25. Bayer Aktiengesellschaft had a positive return on equity of 16.96% and a negative net margin of 2.74%. The company had revenue of $12 billion for the quarter. As a group, equities research analysts predict that Bayer Aktiengesellschaft will post 1.38 earnings per share for the current year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.